Italia markets close in 3 hours 8 minutes
FTSE MIB
33.537,96 -169,25 (-0,50%) Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
81,32 +0,49 (+0,61%) Bitcoin EUR
57.491,88 +338,18 (+0,59%)
NBIX Sep 2024 160.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 01:34PM EDT. Mercato aperto.
| Chiusura precedente | 4,8500 |
| Aperto | 5,7000 |
| Denaro | 0,0000 |
| Domanda | 0,0000 |
| Prezzo d'esercizio | 160,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 4,0000 - 5,7000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,21k |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.